
    
      Primary colorectal carcinoma is one of the most common malignancies in China, Immunotherapy
      is considered to be one of the most promising means of human against cancer. This is a phase
      II clinical trial of single- center, The investigators plan to recruit for 90 patients with
      advanced colorectal cancer,and all patients are divided into three groups.one group will
      receive cryotherapy, one group will receive conventional therapyï¼Œand the rest one will
      receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with
      cryotherapy.

      The result of this study was statistic and analysed with the record of Response Evaluation
      Criteria In Solid Tumors(RECIST1.1) evaluation standard.
    
  